NCT04722172 - A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 21, 2021

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Interventions

DRUG

Acalabrutinib

Acalabrutinib for a minimum of 13 cycles and maximum 26 cycles.

DRUG

Obinutuzumab

Obinutuzumab will be administered during Cycles 2-7.

Trial Locations (8)

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

Memorial Sloan Kettering Westchester (All protocol activities), Harrison

Memorial Sloan Kettering Nassau (All protocol activities), Uniondale

Memorial Sloan Kettering Commack (All protocol activities), Commack

Memorial Sloan Kettering Basking Ridge (All protocol activities), Basking Ridge

Hackensack Meridian Health (Data collection only), Hackensack

Memorial Sloan Kettering Monmouth (All protocol activities), Middletown

Memorial Sloan Kettering Bergen (All protocol activities), Montvale